Welcome to our dedicated page for Prenetics news (Ticker: PRE), a resource for investors and traders seeking the latest updates and insights on Prenetics stock.
Prenetics Global Limited reports developments around its consumer health sciences business, led by IM8, a premium health and longevity brand focused on daily nutrition and supplementation. Company updates commonly cover IM8 product lines such as Daily Ultimate Essentials, Daily Ultimate Longevity and The Beckham Stack, as well as brand partnerships across professional sports, preventive health testing and nutrition-access initiatives.
Recurring Prenetics news also includes financial results, earnings calls, revenue and profitability commentary, share repurchase activity, executive share purchases, balance-sheet positioning and capital allocation. Recent corporate updates reflect the company’s strategic focus on IM8 following divestitures and a shift away from digital-asset treasury expansion.
Prenetics Global Limited (NASDAQ: PRE), a leader in genomic and diagnostic testing, announced its participation in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference from February 14 to 16, 2023. Founded in 2014, Prenetics aims to decentralize healthcare by making consumer health, clinical care, and medical genomics accessible worldwide. The company operates in nine locations, including the UK, Hong Kong, and India, and offers services such as genetic testing, colorectal cancer screening, and COVID-19 testing. The event underscores Prenetics' commitment to innovation in health and diagnostics.
F.N.B. Corporation (NYSE: FNB) has declared a quarterly cash dividend of $18.13 per share on its Non-Cumulative Perpetual Preferred Stock, Series E (NYSE: FNB.PRE). This dividend is equivalent to $0.45325 per depositary share. The payment will be made on February 15, 2023, to shareholders recorded as of January 31, 2023. With total assets nearing $43 billion and approximately 340 banking offices, FNB operates in several states and D.C., offering comprehensive commercial and consumer banking solutions.
Prenetics Global Limited (NASDAQ: PRE) announced a leadership change with Dr. Bayju Thakar appointed as CEO of Prenetics EMEA, effective immediately. This strategic move is aimed at enhancing the company’s growth in the complex EMEA healthcare market. Dr. Thakar, former CEO of Doctor Care Anywhere, brings over 20 years of healthcare experience and a strong digital health background. With an emphasis on expanding into primary care, IVF, and personalized cancer diagnostics, Prenetics seeks to leverage its robust balance sheet for both organic and inorganic growth opportunities across the region.
Prenetics has acquired a majority stake in ACT Genomics, enhancing its entry into the $80+ billion precision oncology market. ACT Genomics received FDA clearance for its ACTOnco genomic profiling test, the first of its kind from an Asia-based company. This comprehensive test analyzes 440 cancer-related genes to guide therapy decisions for solid tumors, potentially transforming cancer care in Asia. The FDA authorization may lead to insurance coverage and further R&D investment by Prenetics, reflecting a commitment to personalized medicine.
Prenetics Global Limited (NASDAQ: PRE) announced the acquisition of a majority stake in ACT Genomics Holdings for $20 million and 19.9 million shares. This strategic purchase integrates germline and somatic testing, enhancing Prenetics' offerings in the rapidly growing US$80 billion precision oncology market. ACT is expected to contribute US$25-30 million in revenue for 2023, solidifying Prenetics' position in cancer diagnostics. The acquisition is set to complete by December 30, 2022, pending usual conditions.
On November 30, 2022, Prenetics Global Limited (NASDAQ: PRE) announced a $20 million share repurchase program authorized by its board, effective over the next 24 months. This strategic move aims to enhance shareholder value amidst recent stock volatility. Additionally, Prenetics will be included in the MSCI Global Micro Cap Index (Hong Kong), marking a significant milestone. The company expects FY2022 revenues between $270-280 million and adjusted EBITDA of $47-53 million, demonstrating strong financial fundamentals and a robust balance sheet with $250 million in net current assets.
Prenetics Global Limited (NASDAQ: PRE) announced its Q3 2022 financial results, reporting revenues of US$80 million and a loss from operations of US$9 million. The company achieved an adjusted earnings of US$21 million and adjusted EBITDA of US$27 million with a gross margin of 59%. Prenetics ended the quarter with approximately US$250 million in cash. The company raised its full-year revenue guidance to US$270 million to US$280 million and adjusted EBITDA to US$47 million to US$53 million, reflecting strong growth and strategic expansion plans.
Prenetics Global Limited (NASDAQ: PRE) reported second-quarter revenue of US$51.7 million, with a loss from operations of US$(17.9) million. The company achieved an adjusted EBITDA of US$6.5 million and raised its full-year guidance for adjusted EBITDA to US$35 million to US$45 million, with revenue expectations set between US$255 million and US$275 million. The firm launched two new products and has a strong balance sheet with US$215.3 million in cash and equivalents as of June 30, 2022. Upcoming initiatives include a partnership to create a decentralized health data platform.
Prenetics Global Limited (NASDAQ: PRE) announced its Q1 2022 financial results, highlighting a 60.2% year-over-year revenue increase to US$92.0 million. The company reported a loss from operations of US$0.6 million but achieved a record adjusted EBITDA of US$12.7 million. With over US$260 million in cash following its Nasdaq listing, Prenetics is well-positioned for growth, particularly with upcoming product launches including ColoClear and Circle Snapshot. The firm is also making strides in M&A discussions aimed at enhancing its telehealth and personalized care offerings.
Prenetics has officially listed on Nasdaq under ticker symbol PRE as the first Hong Kong unicorn on May 18, 2022, following its business combination with Artisan Acquisition Corp. The transaction yields at least US$260M to support Prenetics' growth, facilitating strategic acquisitions and expansion into EMEA and Southeast Asia. Prenetics reported a 323% year-on-year revenue increase for FY2021, totaling US$275.9 million. The company is advancing M&A discussions in Europe and Southeast Asia, with an aim to enhance its genomic and diagnostic testing services.